surmount-osa trial tirzepatide results Excess adiposity is a reversible etiologic risk factor for obstructive sleep apnea. In a new trial, reduced the apnea hypopnea index of participants with obstructive sleep apnea and obesity. Read the Tirzepatide SURMOUNTs obstructive sleep apnea,

Risbud MV, Shapiro IM: Notochordal cells in the adult intervertebral disc: new perspective on an old question

In fact, they were named as the 2023 Breakthrough of the Year by Science.org

Among them, 21 patients in the placebo group and 12 in the L-carnitine group were dropped out because of consent withdrawal (16 patients in the placebo group and eight in the L-carnitine group), loss to follow-up (two patients in the placebo group), discontinuation due to adverse events (two patients in the placebo group and three in the L-carnitine group), and discontinuation at the investigators discretion (one patient from each group)

Increase to 0.5mg : After 4 weeks, the dose is typically increased to 0.5mg